Hbvaxpro (Aluminium, Hepatitis B Surface Antigen (Rdna) [produced In S. Cerevisiae Cells By Rdna])

Hbvaxpro is indicated for the prevention of hepatitis B virus infection in persons who have not been previously immunized and for boosting immunity in those with waning protection.

• Primary vaccination series for infants, children, and adolescents.
• Booster doses for adults at risk of exposure, such as healthcare workers.
• Immunization of travelers to regions with high hepatitis B prevalence.
• Use in patients with chronic liver disease to reduce risk of superinfection.
• Administration before dialysis or organ transplantation when hepatitis B immunity is required.

Following intramuscular or subcutaneous injection, Hbvaxpro may cause a range of transient reactions, most of which are mild and resolve without intervention. These reactions typically appear within hours to a few days after vaccination and are self‑limiting.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever.
• Fatigue or mild headache.
• Nausea or mild gastrointestinal discomfort.
• Muscle aches.
• Mild rash.

Serious

• Severe allergic reaction (anaphylaxis).
• Guillain‑Barré syndrome (rare).
• Thrombocytopenia or other hematologic abnormalities.
• Seizures (very rare).

Healthcare providers should assess individual risk factors and medical history before administering Hbvaxpro to ensure safe and effective immunization.

• Do not vaccinate individuals with a known severe allergy to any vaccine component, including aluminium salts.
• Defer vaccination in persons experiencing acute moderate or severe illness until recovery.
• Use caution in patients with a history of hypersensitivity to hepatitis B vaccines.
• Evaluate immune status in immunocompromised patients; vaccine may be less effective.
• Pregnant or breastfeeding women should discuss potential benefits and risks with a clinician.
• Monitor for signs of anaphylaxis for at least 15 minutes post‑injection.

Hbvaxpro does not have many documented drug‑drug interactions, but certain medications and conditions may influence its safety or immunogenicity.

Avoid

• Concurrent administration of immunosuppressive agents (e.g., high‑dose corticosteroids) that may diminish vaccine response.
• Simultaneous receipt of other live vaccines without appropriate interval.

Use with caution

• Antiviral therapy for chronic hepatitis B; timing should be coordinated to avoid interference with antibody development.
• Blood products or immunoglobulins given within 3 months may reduce vaccine efficacy.
• Patients on allergy‑inducing medications (e.g., beta‑lactams) should be observed for enhanced local reactions.